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Summary and Implications  
Synchronization of ovulation is a common reproductive 
management practice in the US dairy cattle industry. The 
objective of this study was to compare two different sites of 
hormone administration (intralabial versus intramuscular) 
and two different manufacturers (Parnell versus Zoetis) of 
the reproductive hormones gonadotropin releasing hormone 
(GnRH) and prostaglandin F2α (PGF) on the efficacy of 
ovulation induction. Holstein cows (n=388) were enrolled in 
a pre-synch/ovsynch protocol during this 14-month study. 
Ultrasonographic observation of ovaries was made eight 
days after timed artificial insemination (TAI). Overall, 
treatment had no effect on the proportion of cows (90.0%) 
that ovulated in response to treatment. The incidence of 
double ovulations was 20.6% but was not affected by 
treatment. Similarly, treatment had no effect on the 
incidence of ovarian cysts (8.8%). Results revealed that 
failure to ovulate in response to exogenous hormone 
treatment caused a 10% reduction in potential pregnancy 
rate. There was no difference in efficacy of ovulation 
induction due to manufacturer of products, indicating that 
producers have a choice of products they can use. Intralabial 
administration of reproductive hormones was equally 
effective as intramuscular injection for the induction of 
ovulation, and intralabial injection should be considered a 
viable administration site because it can eliminate injection 
site abscesses in carcasses at the time of meat harvest.  
 
Introduction 
Cow reproductive efficiency directly influences the 
profitability of every dairy farm. One obvious reason why 
reproduction impacts profitability is because cows must 
become pregnant and give birth in order to initiate lactation. 
Without lactation, farmers are unable to obtain product 
(milk) they can sell to generate income.  
The US dairy cattle industry has made phenomenal 
strides in breeding cows with high genetic potential for milk 
production; however, one of the adverse consequences of 
this increased level of milk production has been a decline in 
cow reproductive efficiency. Fortunately, the dairy industry 
has identified genetic traits (e.g., daughter pregnancy rate, 
sire conception rate, genomic haplotypes deleterious to 
reproduction) that are effective tools for dairy farmers to use 
to slowly reverse the decline in reproductive performance. 
Another consequence of genetic selection for increased 
milk production in dairy cattle has been an increase in the 
proportion of cows with high metabolic rates. Although 
rapid metabolism is very helpful to make nutrients available 
for milk synthesis, it has likely led to a reduction in the 
duration of the period of estrus because the reproductive 
hormone responsible for expression of heat (estrogen) is 
also being metabolized more quickly. A reduction in the 
duration of estrus increases the likelihood that a dairy 
farmer fails to detect all cows in heat, and this negatively 
impacts reproductive efficiency. 
To overcome potential difficulties with detection of 
estrus, protocols were developed to facilitate breeding of 
dairy cows without the need to detect heat. These protocols 
are commonly known as synchronization of ovulation 
protocols. Although protocols vary, synchronization of 
ovulation typically involves administration of two 
exogenous reproductive hormones - gonadotropin releasing 
hormone (GnRH) and prostaglandin F2α (PGF). These 
hormones typically are administered intramuscularly.   
One of the potential concerns associated with the 
intramuscular injection of reproductive hormones (as well as 
all other products) is the possible formation of abscesses at 
the site of injection. The dairy edition of the beef quality 
assurance audit conducted in 2007 reported that 11% of 
carcasses from dairy animals had visible injection site 
blemishes. These injection site blemishes must be removed 
before the meat enters the human food chain (and this 
removal is a cost passed to the consumer). If undetected, 
these carcass blemishes represent a potential food safety risk 
associated with intramuscular injections. 
One potential method to circumvent injection site 
abscesses is to give injections of reproductive hormones in a 
part of the animal’s body that is routinely discarded during 
the production of animal-derived foods.  One such location 
is the external genitalia (labia) of the female.     
The objectives of the study were to: 1) evaluate the 
effectiveness of intralabial versus intramuscular 
administration of reproductive hormones routinely used for 
synchronization of ovulation, and 2) compare the 
effectiveness of reproductive hormones produced by two 
different manufacturers (Lutalyse®/Factrel® [Zoetis] vs 
EstroPLAN®/GONAbreed® [Parnell]).  Parnell products 
are relatively new (approved by FDA in March of 2013). 
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Materials and Methods 
This study was initiated in January of 2016 at the Iowa 
State University Dairy farm located near Ames, Iowa, USA. 
A total of 388 Holstein cows of varying parities were 
utilized in this research. Use of animals for this project was 
reviewed and approved by the Iowa State University Animal 
Care and Use Committee (IACUC).  
Postpartum cows that passed the routine reproductive 
exam at approximately 40 days postpartum (range: 36-46 
days) were enrolled in a Pre-Synch/OvSynch protocol as 
illustrated below: 
 
 
Eligible cows were randomly assigned within parity to 
one of four treatment combinations in a 2 X 2 factorial 
treatment arrangement.  Cows were treated with 
reproductive hormones manufactured by either Zoetis or 
Parnell, and cows received their designated reproductive 
hormone treatments either intramuscularly or intralabially. 
Gonadotrophin releasing hormone (GnRH) products 
used for this study were: Factrel® (2 ml dose; 50 μg 
gonadorelin per ml; Zoetis product) or GONAbreed® (1 ml 
dose; 100 μg gonadorelin per ml; Parnell product). 
Prostaglandin F2α (PGF) products used for this study 
were: Lutalyse® (5 ml dose; 5 mg dinoprost tromethamine 
per ml; Zoetis product) or estroPLAN® (2 ml dose; 250 μg 
cloprostenol sodium per ml; Parnell product).      
After receiving all reproductive hormone treatments, 
cows underwent timed artificial insemination (TAI).  Eight 
days after TAI, left and right ovaries of all treated cows 
were examined via use of ultrasonography (EI Medical 
Imaging®, Ibex® EVO®, L6E linear transducer). 
Information was recorded on the number of corpora lutea as 
well as the presence of ovarian cysts. 
Data were analyzed by analysis of variance using the 
PROC GLM procedure in SAS. It should be noted that not 
all cows initially enrolled in this study remained on the 
study until the end of the reproductive hormone treatments. 
In some instances, cows that exhibited a strong heat after the 
second PGF injection of the pre-synch portion of the 
protocol were inseminated at that time (subsequently 
leading to their removal from the study). 
 
Results and Discussion 
Neither the site of reproductive hormone administration 
nor the product manufacturer affected the proportion of 
cows that ovulated, the proportion of cows that possessed 
two or more ovulations, or the proportion of cows with 
ovarian cysts. Overall, 90.0% of cows ovulated in response 
to the synchronization of ovulation protocol, 20.6% of cows 
exhibited multiple ovulations, and 8.8% of cows possessed 
ovarian cysts.  Means (± std dev) by treatment combination 
are shown in Table 1. 
Based on this preliminary analysis, both reproductive 
hormone manufacturers are marketing products that are 
effective in inducing ovulation in postpartum dairy cattle. 
Dairy farmers can choose either manufacturer of products 
and use them with equal confidence.    
The main reason to investigate a site of reproductive 
hormone administration other than the muscle is because 
any intramuscular injection has the potential to create tissue 
damage and/or injection site abscesses in the animal’s 
muscles. In theory, those same damaged muscles could 
subsequently enter the human food chain as a beef roast, 
steak or hamburger, and this would represent a potential 
food safety risk. Although federal inspectors at meat harvest 
facilities are extremely vigilant to prevent damaged product 
from entering the human food chain, a preferred solution to 
this potential problem is to prevent tissue damage altogether 
by reducing the number of intramuscular injections that 
food animals receive.  
There was no difference in the effectiveness of the 
reproductive hormone products given in the muscle or the 
labia. Thus, the beef and dairy cattle industries could adopt 
the intralabial injection site and help reduce the number of 
carcass blemishes and reduce the amount of meat that is 
condemned (determined inedible) due to carcass abscess 
formation. Ultimately, this can increase the amount of beef 
available to consumers for consumption not only in the 
United States but also in export markets.    
This alternate site of injection (in the labia) has been 
previously investigated (please see Youngs et al., 2004, 
Proc. Intl Cong Anim Reprod 1:60), and results of that 
previous also showed that intralabial and intramuscular 
injections were equally effective. 
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Table 1.  Reproductive response of postpartum dairy cows enrolled in a Pre-synch / OvSynch synchronization of ovulation 
protocol and treated with reproductive hormones marketed by different manufacturers and administered in the 
muscle or labia. 
 
 
Product 
manufacturer 
 
Injection  
site 
 
Number 
of cows 
                                        
                                                  Proportion of Cows 
that ovulated with multiple ovulations with ovarian cysts 
 
Parnell 
 
muscle 
 
  96 
 
0.896 ± 0.307 
 
0.313 ± 1.079  
 
0.052 ± 0.223 
 
Parnell 
 
labia 
 
  97 
 
0.887 ± 0.319 
 
0.134 ± 0.342 
 
0.103 ± 0.306 
 
Zoetis 
 
muscle 
 
100 
 
0.900 ± 0.315 
 
0.160 ± 0.368 
 
0.120 ± 0.327 
 
Zoetis 
 
labia 
 
  95 
 
0.916 ± 0.279 
 
0.221 ± 0.417 
 
0.074 ± 0.262 
 
 
